首页 > 最新文献

Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

英文 中文
Terapia de ablación con yodo radiactivo de baja dosis (1,11 GBq) para el cáncer de tiroides diferenciado en el oeste de Turquía 土耳其西部分化型甲状腺癌的低剂量(1.11 GBq)放射性碘消融治疗
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500055
B. Karaşah Erkek , H. Sarıyıldız Gümüşgöz , A. Oral , B. Yazıcı , A. Akgün

Objective

Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90-95% at 10 years) [131I]NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.

Methods

Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110 MBq (30 mCi) [131I]NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.

Results

An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10 ng/ml and 5.35 ng/ml) were associated with unsuccessful ablation.

Conclusions

Our results indicate that a 1110 MBq (30 mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6-12  onths later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.
目的对低风险的分化型甲状腺癌(DTC)病例进行消融治疗,通过消除残留的甲状腺组织,将甲状腺球蛋白(Tg)水平降至术后可测量水平以下,从而便于对患者进行监测。然而,有效消融所需的最小活性剂量仍不确定。选择低剂量[131I]NaI进行消融为患者和医疗服务提供了多项优势。特别是对于预期寿命较长(10 年内约为 90-95%)的这类肿瘤患者,[131I]NaI 治疗不应对患者治疗后的生活构成风险,也不会影响他们的生活质量。方法回顾性研究了 287 名接受低剂量 1110 MBq(30 mCi)[131I]NaI 消融治疗的 DTC 患者的临床数据、实验室检查结果和影像学检查。消融后的造影和实验室检查结果分为消融成功/失败两类。成功消融组是根据 ATA 标准中概述的极佳反应标准确定的。分析了临床、病理结果、生化常见变量与治疗失败之间的关系。结果 根据 ATA 标准,77% 的患者在消融术后获得了极佳反应。结论我们的研究结果表明,1110 MBq(30 mCi)的消融剂量足以使大多数低风险 DTC 病例在 6-12 个月后获得极佳反应。在选择消融剂量时,除了指南中提到的组织学标志物和年龄外,我们还发现刺激 Tg 值和性别可能是预测消融成功的重要因素。
{"title":"Terapia de ablación con yodo radiactivo de baja dosis (1,11 GBq) para el cáncer de tiroides diferenciado en el oeste de Turquía","authors":"B. Karaşah Erkek ,&nbsp;H. Sarıyıldız Gümüşgöz ,&nbsp;A. Oral ,&nbsp;B. Yazıcı ,&nbsp;A. Akgün","doi":"10.1016/j.remn.2024.500055","DOIUrl":"10.1016/j.remn.2024.500055","url":null,"abstract":"<div><h3>Objective</h3><div>Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [<sup>131</sup>I]NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90-95% at 10<!--> <!-->years) [<sup>131</sup>I]NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.</div></div><div><h3>Methods</h3><div>Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110<!--> <!-->MBq (30<!--> <!-->mCi) [<sup>131</sup>I]NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.</div></div><div><h3>Results</h3><div>An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10<!--> <!-->ng/ml and 5.35<!--> <!-->ng/ml) were associated with unsuccessful ablation.</div></div><div><h3>Conclusions</h3><div>Our results indicate that a 1110 MBq (30<!--> <!-->mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6-12<!--> <!--> onths later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500055"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluación del papel de la sarcopenia y de los parámetros de la PET/TC con [18F]FDG en el pronóstico del adenocarcinoma ductal de páncreas 评估肌肉疏松症和 [18F]FDG PET/CT 参数在胰腺导管腺癌预后中的作用。
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500046
H. Önner, M.N. Calderon Tobar, L. Perktaş, F. Yilmaz, G. Kara Gedik
This study investigates the relationship between 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters, clinicopathological characteristics, and sarcopenia in patients with pancreatic ductal adenocarcinoma (PDAC) and evaluates their prognostic roles.

Material and methods

The primary tumor's maximum standard uptake (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) values, as well as clinicopathological factors, were evaluated retrospectively. Computed tomography (CT) was used to assess the skeletal muscle index (SMI). Sarcopenia was defined based on SMI calculated at the third lumbar vertebra (L3). SMI cut-off values for sarcopenia were accepted as 44.77 cm2/m2 for men and 32.50 cm2/m2 for women. The primary endpoint was the overall survival (OS). OS data were analyzed by the Kaplan-Meier method and compared using the log-rank test. To identify predictive factors for sarcopenia, multivariable logistic regression was used following univariable logistic regression. Cox proportional hazards regression analyses were used to find predictors of OS.

Results

Of the 86 patients included in the study, 37 (43%) were diagnosed with sarcopenia. Compared with non-sarcopenic patients, sarcopenia was observed in older patients (P = .028) and patients with lower body mass index (BMI) (P = .001). Age and BMI independently predicted sarcopenia. Univariate analysis identified sarcopenia, advanced stage, and higher primary tumor TLG as significant predictors of overall survival. Multivariate Cox regression analysis revealed that the advanced tumor stage (P = .017) and higher TLG (P = .042) independently predicted OS. The median OS was 9.4 months in non-sarcopenic patients and 5.0 months in sarcopenic patients (P = .021).

Conclusion

In this study cohort, advanced-stage disease and higher primary tumor TLG were identified as independent predictors of OS in patients with PDAC. Additionally, we emphasize the importance of incorporating [18F]FDG PET/CT-derived sarcopenia assessments into the prognostic evaluation and clinical management of PDAC patients. While sarcopenia was associated with shorter OS in univariate analysis, it was not an independent predictor in multivariate analysis.
本研究探讨了胰腺导管腺癌(PDAC)患者的18F-氟脱氧葡萄糖([18F]FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)代谢参数、临床病理特征和肌肉疏松症之间的关系,并评估其预后作用。材料与方法 对原发肿瘤的最大标准摄取量(SUVmax)、代谢肿瘤体积(MTV)和总病变糖酵解(TLG)值以及临床病理因素进行了回顾性评估。计算机断层扫描(CT)用于评估骨骼肌指数(SMI)。根据第三腰椎(L3)计算的 SMI 值来定义肌肉疏松症。肌肉疏松症的 SMI 临界值男性为 44.77 cm2/m2,女性为 32.50 cm2/m2。主要终点是总生存期(OS)。OS 数据采用 Kaplan-Meier 法进行分析,并使用对数秩检验进行比较。为了确定肌肉疏松症的预测因素,在单变量逻辑回归之后采用了多变量逻辑回归。结果 在纳入研究的86名患者中,有37人(43%)被确诊为肌肉疏松症。与非肌肉疏松症患者相比,年龄较大的患者(P = .028)和体重指数(BMI)较低的患者(P = .001)会出现肌肉疏松症。年龄和体重指数可独立预测肌肉疏松症。单变量分析发现,肌肉疏松症、晚期和原发肿瘤 TLG 较高是总生存率的重要预测因素。多变量 Cox 回归分析显示,肿瘤晚期(P = .017)和原发肿瘤 TLG 较高(P = .042)可独立预测 OS。结论在本研究队列中,晚期疾病和原发肿瘤TLG较高被认为是PDAC患者OS的独立预测因素。此外,我们还强调了将[18F]FDG PET/CT 衍生的肌肉疏松症评估纳入 PDAC 患者预后评估和临床管理的重要性。在单变量分析中,肌肉疏松症与较短的OS相关,但在多变量分析中,它并不是一个独立的预测因素。
{"title":"Evaluación del papel de la sarcopenia y de los parámetros de la PET/TC con [18F]FDG en el pronóstico del adenocarcinoma ductal de páncreas","authors":"H. Önner,&nbsp;M.N. Calderon Tobar,&nbsp;L. Perktaş,&nbsp;F. Yilmaz,&nbsp;G. Kara Gedik","doi":"10.1016/j.remn.2024.500046","DOIUrl":"10.1016/j.remn.2024.500046","url":null,"abstract":"<div><div>This study investigates the relationship between <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters, clinicopathological characteristics, and sarcopenia in patients with pancreatic ductal adenocarcinoma (PDAC) and evaluates their prognostic roles.</div></div><div><h3>Material and methods</h3><div>The primary tumor's maximum standard uptake (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) values, as well as clinicopathological factors, were evaluated retrospectively. Computed tomography (CT) was used to assess the skeletal muscle index (SMI). Sarcopenia was defined based on SMI calculated at the third lumbar vertebra (L3). SMI cut-off values for sarcopenia were accepted as 44.77<!--> <!-->cm<sup>2</sup>/m<sup>2</sup> for men and 32.50<!--> <!-->cm<sup>2</sup>/m<sup>2</sup> for women. The primary endpoint was the overall survival (OS). OS data were analyzed by the Kaplan-Meier method and compared using the log-rank test. To identify predictive factors for sarcopenia, multivariable logistic regression was used following univariable logistic regression. Cox proportional hazards regression analyses were used to find predictors of OS.</div></div><div><h3>Results</h3><div>Of the 86 patients included in the study, 37 (43%) were diagnosed with sarcopenia. Compared with non-sarcopenic patients, sarcopenia was observed in older patients (<em>P</em> <!-->=<!--> <!-->.028) and patients with lower body mass index (BMI) (<em>P</em> <!-->=<!--> <!-->.001). Age and BMI independently predicted sarcopenia. Univariate analysis identified sarcopenia, advanced stage, and higher primary tumor TLG as significant predictors of overall survival. Multivariate Cox regression analysis revealed that the advanced tumor stage (<em>P</em> <!-->=<!--> <!-->.017) and higher TLG (<em>P</em> <!-->=<!--> <!-->.042) independently predicted OS. The median OS was 9.4<!--> <!-->months in non-sarcopenic patients and 5.0<!--> <!-->months in sarcopenic patients (<em>P</em> <!-->=<!--> <!-->.021).</div></div><div><h3>Conclusion</h3><div>In this study cohort, advanced-stage disease and higher primary tumor TLG were identified as independent predictors of OS in patients with PDAC. Additionally, we emphasize the importance of incorporating [<sup>18</sup>F]FDG PET/CT-derived sarcopenia assessments into the prognostic evaluation and clinical management of PDAC patients. While sarcopenia was associated with shorter OS in univariate analysis, it was not an independent predictor in multivariate analysis.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500046"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asociación entre las imágenes SPECT/CT con 99mTc-PSMA y los niveles de antígeno prostático específico (PSA) y fosfatasa alcalina (ALP) después de la terapia endocrina en pacientes con cáncer de próstata y metástasis óseas 前列腺癌骨转移患者接受内分泌治疗后,99m锝-PSMA SPECT/CT 成像与前列腺特异性抗原 (PSA) 和碱性磷酸酶 (ALP) 水平之间的关系。
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500054
X. Ruan , Y. Gao

Aim

To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.

Methods

A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and P < 0.05 was statistically significant.

Results

All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA > 1.13 ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was >86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher's exact probability method were statistically significant (P < 0.05, P = 0.006, and P = 0.006, respectively), and ALP level was not statistically significant (P = 0.563).

Conclusion

99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA > 1.13 ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is >86U/L, 99mTc-PSMA imaging has higher specificity.
目的研究接受内分泌治疗的前列腺癌(PCa)骨转移患者中,99m锝-PSMA SPECT/CT检测到的阳性病灶与血液中前列腺特异性抗原(PSA)和碱性磷酸酶(ALP)水平之间的关系。方法对43例确诊为PCa骨转移并接受内分泌治疗的患者进行回顾性分析。收集了所有患者的 PSA、ALP、全身骨成像和 99mTc-PSMA SPECT/CT 成像(其中 17 例患者再次接受了 99mTc-PSMA SPECT/CT 成像检查)。根据首次 99mTc-PSMA SPECT/CT 成像检测骨转移的结果,将所有病例分为两组:阳性组和阴性组。采用 ROC 曲线分析 99mTc-PSMA 成像与 PSA 和 ALP 的关系。采用 Fisher 精确概率法检测 17 例患者治疗后影像学放射性摄取量、PSA 和 ALP 水平的变化,P < 0.05 有统计学意义。首次 99mTc-PSMA SPECT/CT 成像显示 31 例骨转移阳性,12 例骨转移阴性。PSA 和 ALP 的 ROC 曲线分析,AUC 分别为 0.778 和 0.770。当 PSA 为 1.13 ng/mL 时,99m锝-PSMA SPECT/CT 成像诊断敏感性为 93.55%,特异性为 66.67%。当 ALP 为 86U/L 时,99m锝-PSMA SPECT/CT 成像的诊断敏感性为 64.52%,特异性为 83.33%。17 例患者中,7 例 PSA 水平下降,10 例上升。10例ALP水平升高,7例ALP水平降低。在第二次99m锝-PSMA成像病灶中,有9例摄取减少或无摄取,8例摄取增加或病灶数量增加。结论99m锝-PSMA SPECT/CT成像可发现PCa骨转移灶,与PSA水平有关。当PSA为1.13 ng/mL时,诊断和检测阳性骨转移灶的敏感性更高;当ALP为86U/L时,99m锝-PSMA成像具有更高的特异性。
{"title":"Asociación entre las imágenes SPECT/CT con 99mTc-PSMA y los niveles de antígeno prostático específico (PSA) y fosfatasa alcalina (ALP) después de la terapia endocrina en pacientes con cáncer de próstata y metástasis óseas","authors":"X. Ruan ,&nbsp;Y. Gao","doi":"10.1016/j.remn.2024.500054","DOIUrl":"10.1016/j.remn.2024.500054","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and <em>P</em> <!-->&lt;<!--> <!-->0.05 was statistically significant.</div></div><div><h3>Results</h3><div>All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA<!--> <!-->&gt;<!--> <!-->1.13<!--> <!-->ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was &gt;86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher's exact probability method were statistically significant (<em>P</em> <!-->&lt;<!--> <!-->0.05, <em>P</em> <!-->=<!--> <!-->0.006, and <em>P</em> <!-->=<!--> <!-->0.006, respectively), and ALP level was not statistically significant (<em>P</em> <!-->=<!--> <!-->0.563).</div></div><div><h3>Conclusion</h3><div>99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA<!--> <!-->&gt;<!--> <!-->1.13<!--> <!-->ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is &gt;86U/L, 99mTc-PSMA imaging has higher specificity.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500054"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Riñón supernumerario fusionado al istmo de un riñón en herradura, con nefroblastoma posterior, identificado en un renograma isotópico 在同位素肾图上发现与马蹄肾峡部融合的肾脏,伴有后肾母细胞瘤。
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500058
S. Bondia-Bescós , L.J. Pregil , L. Biassoni
{"title":"Riñón supernumerario fusionado al istmo de un riñón en herradura, con nefroblastoma posterior, identificado en un renograma isotópico","authors":"S. Bondia-Bescós ,&nbsp;L.J. Pregil ,&nbsp;L. Biassoni","doi":"10.1016/j.remn.2024.500058","DOIUrl":"10.1016/j.remn.2024.500058","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500058"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiosinoviortesis con [90Y] citrato de ytrio en la sinovitis refractaria de rodilla: experiencia de 2 hospitales de referencia 用枸橼酸[90Y]钇治疗难治性膝关节滑膜炎:两家转诊医院的经验
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500052
I. Bolívar Roldán , Ana Moreno Ballesteros , C. Martínez Chinchilla , A. Jiménez-Heffernan , M.C. Calvo Morón

Introduction

To describe the therapeutic efficacy of radiosynoviorthesis with [90Y]Yttrium citrate (90Y), in patients with chronic knee synovitis refractory to systemic treatments and/or infiltrations, correlating the results with the different etiologies and degenerative changes that they showed, in order to optimize the indication of the technique.

Material and methods

Observational retrospective study with 32 patients (22 men and 10 women) and 34 knees, with refractory chronic knee synovitis, who underwent radiosynoviorthesis between January 2013 and December 2022. Its efficacy was described and analyzed by the subjective improvement referred by the patients and its relationship with the existing etiologies and radiological degenerative changes, expressed by the Kellgren-Lawrence (K-L) scale.

Results

A statistically significant subjective improvement was observed in 70.6% of the cases (P< .001). There were 92.3% of cases with absent, doubtful or mild degenerative changes (K-L 0-2) who improved, while only 50% with moderate or severe changes (K-L 3-4) improved, showing statistically significant differences (P = .03). Among patients with chronic inflammatory origin of synovitis (spondyloarthropathies and rheumatoid arthritis), 80% improved, while in those with osteoarthritis (degenerative) origin, only 25% improved with statistically significant differences (P = .006).

Conclusions

Radiosynoviorthesis with 90Y is an effective treatment in patients with knee refractory chronic synovitis, especially in the presence of mil degenerative joint changes and chronic inflammatory origin. We must ensure the appropiate selection of patients according to these criteria.
引言描述使用[90Y]枸橼酸钇(90Y)进行放射ynoviorthesis对全身治疗和/或浸润难治性慢性膝关节滑膜炎患者的疗效,并将结果与不同病因和退行性病变相关联,以优化该技术的适应症。材料与方法回顾性观察研究在2013年1月至2022年12月期间,对32名难治性慢性膝关节滑膜炎患者(22男10女)和34个膝关节进行了放射综合治疗。根据患者的主观改善情况及其与现有病因和放射学退行性病变的关系(用 Kellgren-Lawrence (K-L) 量表表示),对其疗效进行了描述和分析。结果 70.6% 的病例主观改善情况具有统计学意义(P< .001)。92.3%的病例无退行性病变、退行性病变可疑或轻度退行性病变(K-L 0-2),而只有 50%的病例有中度或重度退行性病变(K-L 3-4),差异有统计学意义(P = .03)。在慢性炎症性滑膜炎(脊柱关节病和类风湿性关节炎)患者中,80% 的患者病情有所改善,而在骨关节炎(退行性)患者中,只有 25% 的患者病情有所改善,差异有统计学意义(P = .006)。我们必须确保根据这些标准适当选择患者。
{"title":"Radiosinoviortesis con [90Y] citrato de ytrio en la sinovitis refractaria de rodilla: experiencia de 2 hospitales de referencia","authors":"I. Bolívar Roldán ,&nbsp;Ana Moreno Ballesteros ,&nbsp;C. Martínez Chinchilla ,&nbsp;A. Jiménez-Heffernan ,&nbsp;M.C. Calvo Morón","doi":"10.1016/j.remn.2024.500052","DOIUrl":"10.1016/j.remn.2024.500052","url":null,"abstract":"<div><h3>Introduction</h3><div>To describe the therapeutic efficacy of radiosynoviorthesis with [<sup>90</sup>Y]Yttrium citrate (<sup>90</sup>Y), in patients with chronic knee synovitis refractory to systemic treatments and/or infiltrations, correlating the results with the different etiologies and degenerative changes that they showed, in order to optimize the indication of the technique.</div></div><div><h3>Material and methods</h3><div>Observational retrospective study with 32 patients (22 men and 10 women) and 34 knees, with refractory chronic knee synovitis, who underwent radiosynoviorthesis between January 2013 and December 2022. Its efficacy was described and analyzed by the subjective improvement referred by the patients and its relationship with the existing etiologies and radiological degenerative changes, expressed by the Kellgren-Lawrence (K-L) scale.</div></div><div><h3>Results</h3><div>A statistically significant subjective improvement was observed in 70.6% of the cases <em>(P</em>&lt;<!--> <!-->.001). There were 92.3% of cases with absent, doubtful or mild degenerative changes (K-L 0-2) who improved, while only 50% with moderate or severe changes (K-L 3-4) improved, showing statistically significant differences <em>(P</em> <!-->=<!--> <!-->.03). Among patients with chronic inflammatory origin of synovitis (spondyloarthropathies and rheumatoid arthritis), 80% improved, while in those with osteoarthritis (degenerative) origin, only 25% improved with statistically significant differences <em>(P</em> <!-->=<!--> <!-->.006).</div></div><div><h3>Conclusions</h3><div>Radiosynoviorthesis with <sup>90</sup>Y is an effective treatment in patients with knee refractory chronic synovitis, especially in the presence of mil degenerative joint changes and chronic inflammatory origin. We must ensure the appropiate selection of patients according to these criteria.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500052"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET/RM cardiovascular con [18F]F-FDG en el diagnóstico de miocardiopatía aguda inflamatoria 用[18F]F-FDG进行心血管正电子发射计算机断层显像/MR,诊断急性炎症性心肌病
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500038
J.R. Garcia, R. Olivero, M. Panelo, L. Mont, L. Pinilla, M.E. Riera, A. Maceira
{"title":"PET/RM cardiovascular con [18F]F-FDG en el diagnóstico de miocardiopatía aguda inflamatoria","authors":"J.R. Garcia,&nbsp;R. Olivero,&nbsp;M. Panelo,&nbsp;L. Mont,&nbsp;L. Pinilla,&nbsp;M.E. Riera,&nbsp;A. Maceira","doi":"10.1016/j.remn.2024.500038","DOIUrl":"10.1016/j.remn.2024.500038","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500038"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141702559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heterogeneidad del tumor primario en la PET/TC con [68Ga]Ga-PSMA previa al tratamiento para la predicción de la recurrencia bioquímica en el cáncer de próstata 用于预测前列腺癌生化复发的治疗前[68Ga]Ga-PSMA PET/CT 原发肿瘤异质性
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500032
S. Gülbahar Ateş , B.B. Demirel , E. Kekilli , E. Öztürk , G. Uçmak

Purpose

The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.

Methods

Fifty-one patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.

Results

Twenty-nine (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (P=.050), GLCM-sum variance (P=.019), and GLCM-cluster prominence (P=.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (P=.009) and GLCM-sum variance (P=.004) were found as independent predictors of BCR in the multivariate analysis.

Conclusion

Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.
目的 研究治疗前[68Ga]Ga-PSMA PET中原发肿瘤的纹理分析在预测接受明确治疗的前列腺癌患者发生生化复发(BCR)中的价值。方法 纳入51例接受治疗前[68Ga]Ga-PSMA-11 PET/CT检查并接受明确放疗(RT)或根治性前列腺切除术(RP)的前列腺腺癌患者。研究人员记录了患者的人口统计学特征、临床病理学特征、是否存在 BCR 以及最后一次随访日期。利用LifeX程序从PET/CT图像中获取纹理参数和常规PET参数(最大标准化摄取值(SUVmax)、总病灶-PSMA(TL-PSMA)和PSMA-肿瘤体积(PSMA-TV))。在 ROC 分析中使用尤登指数对参数进行分组。结果29例(56.9%)患者接受了初治RT,其余22例(43.1%)患者接受了RP。5例(22.7%)RP患者和3例(10.3%)根治性RT患者在随访期间出现了BCR。INTENSITY-BASED-minimum grey level(P=.050)、GLCM-sum variance(P=.019)和 GLCM-cluster prominence(P=.050)在单变量分析中与 BCR 相关。结论治疗前[68Ga]Ga-PSMA PET 显示的肿瘤异质性与接受明确疗法的 PCa 患者发生 BCR 的高风险有关。
{"title":"Heterogeneidad del tumor primario en la PET/TC con [68Ga]Ga-PSMA previa al tratamiento para la predicción de la recurrencia bioquímica en el cáncer de próstata","authors":"S. Gülbahar Ateş ,&nbsp;B.B. Demirel ,&nbsp;E. Kekilli ,&nbsp;E. Öztürk ,&nbsp;G. Uçmak","doi":"10.1016/j.remn.2024.500032","DOIUrl":"10.1016/j.remn.2024.500032","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.</div></div><div><h3>Methods</h3><div>Fifty-one patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.</div></div><div><h3>Results</h3><div>Twenty-nine (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (<em>P</em>=.050), GLCM-sum variance (<em>P</em>=.019), and GLCM-cluster prominence (<em>P</em>=.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (<em>P</em>=.009) and GLCM-sum variance (<em>P</em>=.004) were found as independent predictors of BCR in the multivariate analysis.</div></div><div><h3>Conclusion</h3><div>Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500032"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Papel de la [18F]FDG PET/TC en la valoración del carcinoma ductal infiltrante de mama inflamatorio: a propósito de un caso 18F]FDG PET/CT 在评估炎症浸润性乳腺导管癌中的作用:病例报告
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500057
B. Hervás-Sanz , I.E. Sánchez-Rodríguez , A. Fernández-Ortega , P. Perlaza-Jiménez , M. Cortés-Romera , J. Suils-Ramón
{"title":"Papel de la [18F]FDG PET/TC en la valoración del carcinoma ductal infiltrante de mama inflamatorio: a propósito de un caso","authors":"B. Hervás-Sanz ,&nbsp;I.E. Sánchez-Rodríguez ,&nbsp;A. Fernández-Ortega ,&nbsp;P. Perlaza-Jiménez ,&nbsp;M. Cortés-Romera ,&nbsp;J. Suils-Ramón","doi":"10.1016/j.remn.2024.500057","DOIUrl":"10.1016/j.remn.2024.500057","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500057"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determinación de la acomodación fúndica en gammagrafía de vaciamiento gástrico. Valoración de su utilidad clínica 胃排空闪烁扫描中胃底容积的测定。评估其临床实用性
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500051
J.R. Infante, A. Utrera, A. Baena, R. Barco, A. Martínez, C. Durán, P. Jiménez, J. Serrano

Aim

Gastric emptying scintigraphy is used to assess patients with symptoms of dyspepsia or gastroparesis. An alteration of fundus accommodation may explain these symptoms. The aim of this study was to determine the accommodation in gastric emptying scintigraphy studies performed in our institution.

Material and methods

50 patients (43 children) referred for gastric emptying assessment were evaluated. After fasting for 8 hours, and following international guidelines, egg labeling was performed with 37 mBq of [99mTc]Tc-DTPA and administration of standardized food. Areas of interest were defined in the stomach at different times, and the corresponding retention percentages were calculated. Considering the image at time zero, gastric accommodation was qualitatively and quantitatively assessed, calculating the ratio between proximal stomach counts and total counts.

Results

Of the 50 patients studied, 32 had normal emptying, 10 had slowed emptying and 8 had accelerated emptying. Within the group of patients with normal emptying, 8 had altered accommodation (25%) and another 8 in the group with abnormal emptying (44%). Applying the ROC curve analysis to quantitative values, the most appropriate cut-off value was 0.785 with p< 0.001, sensitivity 82.4% and specificity 100%.

Conclusion

Gastric emptying scintigraphy in addition to determining motility, made it possible to assess both qualitatively and quantitatively the distribution of the radiotracer in the stomach and thus, indirectly, the accommodation in the fundus. It provided added diagnostic information in a simple manner, without protocol changes and allowing more specific treatments to be assessed.
目的胃排空闪烁扫描用于评估有消化不良或胃痉挛症状的患者。胃底容受性的改变可解释这些症状。本研究旨在确定在我院进行的胃排空闪烁成像研究中的胃底容受性。禁食 8 小时后,按照国际指南,使用 37 mBq [99mTc]Tc-DTPA 进行鸡蛋标记,并给予标准食物。在不同时间确定胃中的感兴趣区,并计算相应的滞留率。考虑到零时的图像,对胃容纳量进行定性和定量评估,计算近端胃计数与总计数的比率。在排空正常的患者组中,有 8 人(25%)的胃容纳发生了改变,另有 8 人(44%)的胃排空异常。结论 胃排空闪烁扫描除了能确定胃的蠕动外,还能定性和定量评估放射性示踪剂在胃中的分布,从而间接评估胃底的容积。它以简单的方式提供了更多的诊断信息,无需更改方案,还能评估更多具体的治疗方法。
{"title":"Determinación de la acomodación fúndica en gammagrafía de vaciamiento gástrico. Valoración de su utilidad clínica","authors":"J.R. Infante,&nbsp;A. Utrera,&nbsp;A. Baena,&nbsp;R. Barco,&nbsp;A. Martínez,&nbsp;C. Durán,&nbsp;P. Jiménez,&nbsp;J. Serrano","doi":"10.1016/j.remn.2024.500051","DOIUrl":"10.1016/j.remn.2024.500051","url":null,"abstract":"<div><h3>Aim</h3><div>Gastric emptying scintigraphy is used to assess patients with symptoms of dyspepsia or gastroparesis. An alteration of fundus accommodation may explain these symptoms. The aim of this study was to determine the accommodation in gastric emptying scintigraphy studies performed in our institution.</div></div><div><h3>Material and methods</h3><div>50 patients (43 children) referred for gastric emptying assessment were evaluated. After fasting for 8<!--> <!-->hours, and following international guidelines, egg labeling was performed with 37 mBq of [<sup>99</sup>mTc]Tc-DTPA and administration of standardized food. Areas of interest were defined in the stomach at different times, and the corresponding retention percentages were calculated. Considering the image at time zero, gastric accommodation was qualitatively and quantitatively assessed, calculating the ratio between proximal stomach counts and total counts.</div></div><div><h3>Results</h3><div>Of the 50 patients studied, 32 had normal emptying, 10 had slowed emptying and 8 had accelerated emptying. Within the group of patients with normal emptying, 8 had altered accommodation (25%) and another 8 in the group with abnormal emptying (44%). Applying the ROC curve analysis to quantitative values, the most appropriate cut-off value was 0.785 with p&lt;<!--> <!-->0.001, sensitivity 82.4% and specificity 100%.</div></div><div><h3>Conclusion</h3><div>Gastric emptying scintigraphy in addition to determining motility, made it possible to assess both qualitatively and quantitatively the distribution of the radiotracer in the stomach and thus, indirectly, the accommodation in the fundus. It provided added diagnostic information in a simple manner, without protocol changes and allowing more specific treatments to be assessed.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500051"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carcinoma adrenocortical enorme que simula una masa hepática 巨大肾上腺皮质癌模仿肝脏肿块
IF 1.6 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-01 DOI: 10.1016/j.remn.2024.500060
N. Aydinbelge-Dizdar , D. Cayir , S. Canlar , E.N. Celik , E. Cakal
{"title":"Carcinoma adrenocortical enorme que simula una masa hepática","authors":"N. Aydinbelge-Dizdar ,&nbsp;D. Cayir ,&nbsp;S. Canlar ,&nbsp;E.N. Celik ,&nbsp;E. Cakal","doi":"10.1016/j.remn.2024.500060","DOIUrl":"10.1016/j.remn.2024.500060","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500060"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista Espanola De Medicina Nuclear E Imagen Molecular
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1